semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Diabetes Mellitus, Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Patient must be aged between 18 (inclusive) and 70 years old 2. Patients diagnosed with type 1 or type 2 diabetes according to WHO for at least one year prior to study entry 3. Patient treated by a basal-bolus insulin therapy using an external pump or multiple-daily injections. The insulin regimen has to be stable for the previous six months. NPH insulin use will not be acceptable. 4. Patient should have stable diabetes with a HbA1c between ≥ 7.5 % and < 10.5 % with no keto-acidosis for the previous 6 months. 5. Patient must have a Body Mass Index (BMI) lower than 35 Kg/m² 6. Patient must be willing to undergo all study procedures 7. Patient must be affiliated or beneficiary of a social medical insurance 8. Patient has signed informed consent form prior to study entry  Patient is pregnant, or breast feeding during the period of the study 2. Patient has impaired renal function with a creatinine blood concentration over 150 μmol/L 3. Patient has a liver disease (ALAT, ASAT > 2 x upper limit of normal range) 4. Patient is treated by sulfamides, GLP-1 analogues, DPP-IV inhibitors or glitazones 5. Alcohol or drug addiction, as identified by investigator during screening visit 6. Allergy to sensors or one of their components 7. Manifest psychological disorders 8. Patient health status is not compatible with physical exercise 9. Patient is actively enrolled in another clinical trial or was part of study within 30 days 10. Persons deprived of freedom, adults protected by law or vulnerable persons
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Advanced Cancers Dyspnea Diagnosis of cancer 2. Breakthrough dyspnea, defined in this study as dyspnea on exertion with an average intensity level >=3/10 on the numeric rating scale 3. Outpatient or inpatient at MD Anderson Cancer Center seen by the Supportive Care or Rehabilitation Service 4. Able to communicate in English or Spanish 5. Ambulatory and able to walk with or without walking aid 6. On strong opioids with morphine equivalent daily dose of 30-580 mg, with stable (i.e. +/ ) regular dose over the last 24 hours 7. Karnofsky performance status >=50% 8. Age 18 or older  Dyspnea at rest >=7/10 at the time of enrollment 2. Supplemental oxygen requirement >6 L per minute 3. Delirium (i.e. Memorial delirium rating scale >13) 4. History of unstable angina or myocardial infarction 1 month prior to study enrollment 5. Resting heart rate >120 at the time of study enrollment 6. Systolic pressure >180 mmHg or diastolic pressure >100 mmHg at the time of study enrollment 7. History of active substance abuse within the past 12 months 8. History of allergy to fentanyl 9. Unwilling to provide informed consent
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cardiovascular Disease. Age over 18 years old Diagnosed type 2 diabetes (HbA1C at >6,5%), who are at a risk of CVD indicated with the following risk parameters total cholesterol between 5.0 2 mmol/l (195.0 8 mg/dL) Body Mass Index (BMI) > 25 kg/m2 Waist circumference > 101.6 cm (40 inches) for men and > 88.9 cm (35 inches) for women Triglycerides > 1.7 mmol/L (150mg/dL) HDL-cholesterol < 1 mmol/L (40 mg/dL) for men, < 1.3 mmol/L (50 mg/dL) for women LDL-cholesterol > 2.6 mmol/L (100 mg/dL)  Pregnant or trying to become pregnant or lactating women Subjects unwilling or unable to comply with study procedure Subjects with severe health problems including renal disease, liver disease, cardiovascular disease, and other chronic ill health conditions Subjects on drug cardiovascular medication like warfarin, aspirin Subjects that are taking statins Subjects taking bromelain supplement and other herbal supplements known to be effective e.g. cinnamon Subjects have a history of allergic reactions to bee stings, olive tree pollen or pineapple Subjects have a history of occupational inhalant/skin contact with bromelain Subjects have diabetes ketoacidosis recently (past 2 weeks) Unable to provide informed consent i.e. unable to follow diet control advice or not willing to follow study procedure
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 13.0-30.0,  Diabetes Mellitus, Type 1 Age of 13 to 30 years 2. Subjects must be otherwise healthy except for T1DM, and treated for hypothyroidism if present 3. Menstruating women must have negative pregnancy test. 4. Hemoglobin (Hb) more than 12 g/dl  Having any other chronic condition except hypothyroidism stable on medications 2. On chronic medications that may affect glucose excursions 3. Hemoglobin less than 12 g/dl 4. Positive pregnancy test (based on Urine) 5. Pregnant or lactating mothers 6. Known allergy to Januvia
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 30.0-70.0,  Impaired Glucose Tolerance Men and women with a diagnosis diagnosis of Impaired Glucose Tolerance i.e. fasting plasma glucose less than or equal to 125 mg/dl, 2 hour post 75 gram oral glucose tolerance test (OGTT) plasma glucose between 140-199 mg/dl, glycosylated hemoglobin A1c (HbA1c) less than 6.5% as per American Diabetes Association (ADA) criteria Women of childbearing potential (WOCBP) and men must be using an acceptable method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized  Patients must not be on anti-diabetes therapy for treatment of Impaired Glucose Tolerance (IGT) and must have a fasting plasma glucose concentration less or equal to 125 mg/dl Type 1 or Type 2 diabetes mellitus (fasting plasma glucose greater than 125 mg/dl) Patients must not be on or have received metformin, thiazolidinediones, sulfonylureas, DPP IV inhibitor, or exenatide/liraglutide treatment for treatment of IGT at any time. Patients must not be receiving any of the following medications: thiazide or furosemide diuretics, beta-blockers, or other chronic medications such as hormone replacement therapy with known adverse effects on glucose tolerance levels. Patients taking systemic glucocorticoids will also be excluded Subjects with a history of clinically significant heart disease, peripheral vascular disease, or pulmonary disease Subjects must have a Body Mass Index between 30-35 kg/m2 and stable body weight Subjects must not have clinically significant liver disease (aspartate aminotransferase (AST) < 2.5 times upper limit of normal, Alanine transaminase (ALT) < 2.5 times upper limit of normal, Alkaline phosphatase< 2.5 times upper limit of normal), kidney disease (Serum creatinine < 1.5 mg/dl in men and 1.4 mg/dl in women) or significant anemia (Hematocrit < 34 vol%) Subjects with a history of any serious hypersensitivity reaction to saxagliptin or a dipeptidyl peptidase 4 (DPP-IV) inhibitor Concomitant treatment with systemic cytochrome P450 3A4 inducers Women who are pregnant or breastfeeding
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Inflammation Macrophage Infiltration Cardiovascular Disease 65 yr old HIV infected men and women Stable (at least the past 6 months) on combined antiretroviral therapy (cART) Stable immune (> 300 CD4+ T-cells/µL) and virologic (< 50 copies HIV RNA/mL) status Insulin resistant/impaired glucose tolerance (fasting glucose 100-125mg/dL, or 2-hr glucose 140-200mg/dL or fasting HOMA-IR= 2.5-6.0) Waist circumference > 102 cm (men), > 88 cm (women) BMI > 20 kg/m2 Fasting hypertriglyceridemia > 150 mg/dL Low HDL-cholesterol (< 40 mg/dL in men or < 50 mg/dL in women) Platelet count > 30,000/mm3 Absolute neutrophil count > 750/mm3  Diabetes (T2DM, IDDM or diabetic ketoacidosis) or taking any glucose-lowering medication (e.g., insulin, TZDs, metformin, sulfonylurea) Any agent that might artifactually alter glycemic control (e.g., glucocorticoids, megace, rhGH, GH-secretagogue, testosterone derivatives, creatine monohydrate, chromium picolinate, AA/protein supplements, medium or long-chain fatty acids) during 6 months prior to or during enrollment History of serious CV disease. NYHA Functional Class III or IV (e.g., recent MI, unstable angina, edema, CHF, CAD, CABG, stroke, resting hypertension > 160/95 mmHg), irregular heart rhythm, resting ST-segment depression > 1mm). Treatment with medications for CV condition (e.g., α or ß-blockers). Some BP-lowering medications (Ca++channel blocker, diuretic, or ACE inhibitor) are permitted Moderate to severe renal insufficiency. Serum creatinine > 1.7 mg/dL (men) > 1.5 mg/dL (women) Plan or anticipate a change in anti-HIV medications during the study Lipid-lowering medications are permitted (fibrate or statin or niacin), but must be stable on that agent for at least 6 months prior to enrollment. Lipid-lowering agents cannot be started during the treatment period Chronic hepatitis B (HBV-surface antigen positive). Active hepatitis C (detectable Hep C RNA) Positive urine drug test for opiates, methamphetamine, heroin, cocaine. Active substance abuse that the MD-scientist believes may compromise safety, compliance, interfere with study drug or data interpretation
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Type 1 Diabetes Adult patients with type 1 diabetes Adult, healthy controls  Pregnancy Impaired renal function
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Heart Failure Over the age of 18 years 2. Documented heart failure of ischaemic, idiopathic or hypertensive cause 3. New York Heart Association (NYHA) class II, III or IV symptoms 4. LVEF < 0.40, or no more than 0.35 if NYHA class II and ischaemic aetiology. 5. Receiving ACE inhibitor or ARB (Angiotensin II Receptor Blockers), β-blocker and diuretic therapy at the optimal doses. 6. Has been receiving statin therapy for at least 3 months 7. Willing and able to provide informed consent  Treatment with statins primarily for treatment of hypercholesterolaemia 2. Obstructive or restrictive cardiomyopathy 3. Uncorrected primary valvular disease 4. Active myocarditis 5. Decompensated heart failure or a need for inotropic therapy 6. Myocardial infarction within the past 6 months 7. Unstable angina or stroke within the past 3 months 8. PCI (Percutaneous coronary intervention), CABG (coronary artery bypass graft)or implantation of cardioverter-defibrillator or biventricular pacemaker within the past 3 months or a planned implantation of such a device 9. Previous or planned cardiac transplantation 10. Pericardial disease or systemic disease (eg amyloidosis) 11. Acute or chronic liver disease 12. Alanine and aspartate transminase concentrations more than 1.5 times the upper limit of normal 13. Chronic muscle disease or an unexplained creatinine kinase level of more than 2.5 times the upper limit of normal 14. Serum creatinine level greater than 221 micromol/L 15. Previous treatment with cyclosporine 16. Exercise capacity limited by factors other than cardiac dyspnoea 17. Hospitalisation within one month of randomisation 18. Pregnant or lactating women or women of childbearing potential who were not adequately protected against becoming pregnant 19. Any other concurrent condition that, in the opinion of the investigator, would prevent completion of the clinical trial
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chagas Cardiomyopathy Heart Failure Dilated Cardiomyopathy for were positivity for T cruzi as confirmed by 2 or more serological tests (indirect immunofluorescence, ELISA, and/or indirect hemagglutination) and having cardiomyopathy Cardiomyopathy was present when at least 3 of the following were fulfilled LV enddiastolic diameter (LVDD) N55 mm LVDD/body surface area > 2.7cm/m2 LV ejection fraction (LVEF) < 55% QRS interval > 120 ms echocardiographic evidence of diffuse or segmental systolic wall motion abnormalities  were being pregnant Using any h-blocker Having additional comorbidities (eg, hypertension, diabetes mellitus, thyroid dysfunction, chronic obstructive pulmonary disease, asthma, and renal or hepatic failure)
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Ischemic Cardiomyopathy Nonischemic Cardiomyopathy Heart Failure structural heart disease ischemic or non-ischemic cardiomyopathy  pregnancy age < 18 years old
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-35.0,  Type 1 Diabetes Insulin Dependent Diabetes Juvenile Onset Diabetes Mellitus Autoimmune Diabetes Aged 18 to 35 years Up to 6 months of clinical diagnosis Fasting C-peptide ≥ 0.25 ng / ml HbA1C <9.0% Positive autoantibodies (anti-GAD, Anti-Insulin and Anti-IA2) Without chronic complications  Hepatic, cardiac, pulmonary and hematologic disease
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-35.0,  Elevated Triglycerides Diabetes Cardiovascular Disease Dyslipidemia Males and females, 18-35 years of age South Asian or Caucasian descent through self-identification (South Asians are to have both biological parents with ancestry from India, Pakistan, Sri Lanka, Nepal and Bangladesh and no known non-South Asian ancestry in parents; Caucasians are to have both biological parents who self-identify as Caucasian and no known non-Caucasian ancestry in parents) Body mass index (BMI) 18.0-24.9 kg/m2 with no history of obesity Fasting glucose <100 mg/dL, 2h glucose oral glucose tolerance test (OGTT) < 140 mg/dL triglycerides (TG) <200 mg/dL, HDL cholesterol (HDL-C) >30 mg/dL, LDL cholesterol (LDL-C) <160 mg/dL Willing and able to stop fish oil, fiber supplement, other non-prescribed vitamins/supplements for 1 week prior to visit #2 until completion of study Willing to not drink alcohol for 24-hours before visit #2 Willing and able to provide informed consent  History of diabetes or other endocrine disorder, hepatitis or other liver disorder, HIV, or autoimmune disease Medication(s) known to affect lipids, including hormonal contraceptives Recent acute illness Gastrointestinal disease resulting in significant gastrointestinal dysfunction or malabsorption Cigarette smoking History of ethanol abuse (current intake >2 drinks/day) or illicit drugs History of severe psychiatric illness If female, pregnant or breastfeeding Participation in an investigational drug study within one month of screening Unusual diet or extreme level of physical activity
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Dyspnea Pain Healthy Non-smoking  acute or chronic pain antalgic or psychoactive drugs use nefopam hypersensibility severe allergy diabetes glaucoma prostate adenoma seizure disorder or convulsion history heart or circulation disease pulmonary disease or asthma